 | This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Kissei" – news · newspapers · books · scholar · JSTOR (February 2020) (Learn how and when to remove this message) |
 | |
| ISIN | JP3240600001 |
|---|---|
| Industry | Pharmaceutical products, therapeutic and care foods |
| Founded | August 9, 1946; 78 years ago (1946-08-09) |
| Headquarters | Matsumoto, Nagano, Japan |
| Key people | Mutsuo Kanzawa (CEO) |
| Number of employees | 1504 |
| Website | www |
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
- Difelikefalin
- Fostamatinib (trade name Tavalisse)
- Linzagolix
- Mitiglinide (Glufast)
- Remogliflozin etabonate
- Silodosin (Urief)
- Tranilast (Rizaben)
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China.
References
- "English Home".
- "CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries". www.businesswire.com. 2020-03-27. Retrieved 2020-06-04.
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |
 | This corporation or company article is a stub. You can help Misplaced Pages by expanding it. |